YouTube video by Martha Tilton - Topic

YouTube video by Secular Talk

YouTube video by The Electronic Intifada

Lifecore Biomedical (LFCR) signed an agreement to transfer a currently marketed injectable drug product into its CDMO pipeline and support its commercial manufacturing.The deal, with an unnamed global pharmaceutical company, adds Lifecore’s seventh late-stage commercial program and is the eleventh program added to its pipeline in 2026. The company will perform technical transfer services for a high-viscosity, complex injectable that it describes as strategically important and impactful for patients. Lifecore expects this program to generate commercial revenues in 2028 and states that it is positioned to become one of its largest contracts. With this addition, Lifecore’s late-stage pipeline now contains thirteen programs that could generate commercial revenues by the end of 2028, supporting its strategy of adding high-impact programs and expanding its global customer base.

Lifecore Biomedical (NASDAQ: LFCR) reported second quarter 2026 revenues of $34.2 million, down 6.2% from the comparable prior-year quarter, with gross profit of $12.1 million and a net loss of $6.2 million ($0.19 per diluted share). Adjusted EBITDA* was $8.6 million, compared to $9.1 million a year earlier.For the first six months of 2026, revenues were $57.4 million, down 19.9% year over year, with gross profit of $16.5 million and a net loss of $21.1 million ($0.61 per diluted share). Adjusted EBITDA* was $9.6 million. Lifecore ended the quarter with about $38.8 million in liquidity, including $17.2 million of cash and $21.6 million of revolver availability, and reaffirmed 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA* of $20.5–$25 million. The company signed six new programs in the quarter, bringing 12‑month additions to 13, including eight late‑stage programs, and advanced more than 40 cost and productivity initiatives.